Background. Neonatal infections result in significant morbidity, mortality and increased health care costs. Antibiotics are commonly prescribed to infants hospitalized in the Neonatal Intensive Care Unit (NICU). Broad spectrum antibiotic exposure has been associated with emergence of resistant organisms and disruption in the development of normal flora. There is paucity of data evaluating the appropriateness of antibiotic use in the NICU, based on Centers for Disease Control and Prevention (CDC) 12-Step Guidelines to Prevent Antimicrobial Resistance.
Methods. A retrospective audit of antibiotic use at a tertiary perinatal centre covering four million population was conducted during July 2010 -June 2013. Our objective was to assess the practice of antibiotic therapy for compliance to the recommendations of the CDC 12-step campaign.
Results. We audited vancomycin, meropenem and linezolid use in the NICU. Empirical use >3-day without appropriate specimens collected, or utilization despite narrower spectrum antibiotic available, were considered inappropriate use. 
